AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 26, 2024
32254_dirs_2024-01-26_89fcad21-0bef-4c48-b813-7f0db22179b9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-01-24
Reporting Person: Jones David Scott (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-24 | Common Stock | M | 5600.00 | $12.90 | Acquired | 43562.00 | Direct |
| 2024-01-24 | Common Stock | M | 5700.00 | $3.26 | Acquired | 49262.00 | Direct |
| 2024-01-24 | Common Stock | S | 5700.00 | $25.0094 | Disposed | 43562.00 | Direct |
| 2024-01-24 | Common Stock | S | 5600.00 | $25.0121 | Disposed | 37962.00 | Direct |
| 2024-01-25 | Common Stock | M | 300.00 | $12.90 | Acquired | 38262.00 | Direct |
| 2024-01-25 | Common Stock | M | 300.00 | $3.26 | Acquired | 38562.00 | Direct |
| 2024-01-25 | Common Stock | S | 300.00 | $25.00 | Disposed | 38262.00 | Direct |
| 2024-01-25 | Common Stock | S | 300.00 | $25.00 | Disposed | 37962.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-24 | Stock Option (Right to Buy) | $12.90 | M | 5600.00 | Disposed | 2030-02-28 | Common Stock (5600.00) | Direct |
| 2024-01-24 | Stock Option (Right to Buy) | $3.26 | M | 5700.00 | Disposed | 2033-01-05 | Common Stock (5700.00) | Direct |
| 2024-01-25 | Stock Option (Right to Buy) | $12.90 | M | 300.00 | Disposed | 2030-02-28 | Common Stock (300.00) | Direct |
| 2024-01-25 | Stock Option (Right to Buy) | $3.26 | M | 300.00 | Disposed | 2033-01-05 | Common Stock (300.00) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
F4: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.